Stock NPHC NUTRA PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nutra Pharma Corp.

Equities

NPHC

US67060U2087

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 11:36:38 13/05/2024 pm IST 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Nutra Pharma Corp. 0.00% 0.00%
22/03 Nutra Pharma Corporation Appoints Michael Flax as CFO CI
22/03 Nutra Pharma Corporation Announces Management Changes CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 2.094 1.304 1.203 2.457 7.108 14.65
Enterprise Value (EV) 1 4.695 4.771 4.78 11.06 12.35 22.96
P/E ratio -0.4 x -0.18 x -0.25 x -0.36 x -10.3 x -1.1 x
Yield - - - - - -
Capitalization / Revenue 12.4 x 10.8 x 9.21 x 23.5 x 137 x 150 x
EV / Revenue 27.9 x 39.4 x 36.6 x 106 x 238 x 235 x
EV / EBITDA -2.31 x -3.47 x -3.5 x -9.02 x -13.4 x -11.6 x
EV / FCF -5.48 x -6.04 x -13.2 x 35.2 x 4.88 x 4.36 x
FCF Yield -18.3% -16.6% -7.58% 2.84% 20.5% 23%
Price to Book -0.54 x -0.26 x -0.2 x -0.25 x -0.73 x -0.7 x
Nbr of stocks (in thousands) 2,55,392 18,63,418 40,10,134 49,13,634 59,23,634 73,25,986
Reference price 2 0.008200 0.000700 0.000300 0.000500 0.001200 0.002000
Announcement Date 17/04/17 17/04/18 05/02/21 01/07/21 08/09/21 15/04/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 0.1684 0.121 0.1306 0.1044 0.0519 0.0977
EBITDA 1 -2.035 -1.376 -1.367 -1.226 -0.9211 -1.979
EBIT 1 -2.044 -1.382 -1.373 -1.23 -0.9249 -1.988
Operating Margin -1,213.81% -1,142.3% -1,051.63% -1,178.14% -1,782.27% -2,034.53%
Earnings before Tax (EBT) 1 -3.448 -4.029 -3.885 -6.591 -0.7692 -13.1
Net income 1 -3.448 -4.029 -3.885 -6.591 -0.7692 -13.1
Net margin -2,047.81% -3,330.12% -2,974.59% -6,314.07% -1,482.14% -13,399.01%
EPS 2 -0.0205 -0.003843 -0.001218 -0.001399 -0.000116 -0.001810
Free Cash Flow 1 -0.857 -0.7903 -0.3621 0.3139 2.53 5.27
FCF margin -509.04% -653.26% -277.28% 300.66% 4,875.71% 5,392.63%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/04/17 17/04/18 05/02/21 01/07/21 08/09/21 15/04/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 2.6 3.47 3.58 8.6 5.24 8.3
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.278 x -2.52 x -2.615 x -7.014 x -5.688 x -4.195 x
Free Cash Flow 1 -0.86 -0.79 -0.36 0.31 2.53 5.27
ROE (net income / shareholders' equity) 85.6% 81.5% 68.5% 74.7% 6.63% 80.9%
ROA (Net income/ Total Assets) -424% -286% -323% -319% -180% -230%
Assets 1 0.8124 1.408 1.202 2.063 0.4269 5.7
Book Value Per Share 2 -0.0200 -0 -0 -0 -0 -0
Cash Flow per Share 2 0 - - - - 0
Capex 1 0 0.01 - - 0.01 0.04
Capex / Sales 2.01% 7.53% - - 11.38% 39.95%
Announcement Date 17/04/17 17/04/18 05/02/21 01/07/21 08/09/21 15/04/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NUTRA PHARMA CORP. Stock Nutra Pharma Corp.
0.00% 706K
MODERNA, INC. Stock Moderna, Inc.
+29.61% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.91% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.49% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.77% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.39% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.15% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.96% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NPHC Stock
  4. Financials Nutra Pharma Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW